DexCom, Inc. $DXCM Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 47.6% during the 1st quarter, Holdings Channel reports. The fund owned 152,007 shares of the medical device company’s stock after selling 137,938 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in DexCom were worth $9,546,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in DexCom during the fourth quarter worth $483,356,000. AQR Capital Management LLC grew its holdings in DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after purchasing an additional 2,658,158 shares during the last quarter. Employees Provident Fund Board purchased a new position in shares of DexCom in the fourth quarter valued at $145,352,000. J. Stern & Co. LLP increased its position in shares of DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after buying an additional 1,529,641 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of DexCom by 271.4% during the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after buying an additional 1,509,219 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 2.0%

DexCom stock opened at $74.85 on Wednesday. The stock has a market cap of $28.88 billion, a PE ratio of 31.99, a P/E/G ratio of 1.21 and a beta of 1.45. The stock has a 50-day moving average price of $72.79 and a 200 day moving average price of $69.01. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 EPS. Equities research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at approximately $7,326,353. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 98,506 shares of company stock valued at $7,205,258. 0.28% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on DXCM. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research report on Friday, May 1st. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $91.00 price target on shares of DexCom in a report on Monday, June 8th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $85.40.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.